Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
38
PALI Quote, Financials, Valuation and Earnings
Last price:
$1.64
Seasonality move
:
-9.02%
Day range:
$1.60 - $1.71
52-week range:
$0.53 - $2.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
78.55x
Volume:
2.9M
Avg. volume:
4.9M
1-year change:
66.94%
Market cap:
$252.2M
Revenue:
--
EPS (TTM):
-$4.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PALI
Palisade Bio, Inc.
|
-- | -$0.03 | -100% | -91.4% | $13.40 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.1M | $0.59 | 11.8% | 33.07% | $88.87 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 29.62% | 267.32% | $14.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PALI
Palisade Bio, Inc.
|
$1.69 | $13.40 | $252.2M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.33 | $31.21 | $4.1B | 15.65x | $0.00 | 0% | 3.91x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$339.37 | $457.00 | $45B | 150.36x | $0.00 | 0% | 12.20x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$63.42 | $88.87 | $12.2B | 23.76x | $0.00 | 0% | 4.02x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.35 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.34x |
|
SVRA
Savara, Inc.
|
$5.59 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PALI
Palisade Bio, Inc.
|
6.16% | 3.259 | 2.63% | 1.50x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PALI
Palisade Bio, Inc.
|
-$1K | -$2.9M | -212.65% | -222.18% | -- | -$3.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Palisade Bio, Inc. vs. Competitors
-
Which has Higher Returns PALI or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Palisade Bio, Inc.'s net margin of 25.76%. Palisade Bio, Inc.'s return on equity of -222.18% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About PALI or ACAD?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 692.9%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 28.28%. Given that Palisade Bio, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Palisade Bio, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is PALI or ACAD More Risky?
Palisade Bio, Inc. has a beta of 1.583, which suggesting that the stock is 58.275% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock PALI or ACAD?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or ACAD?
Palisade Bio, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Palisade Bio, Inc.'s net income of -$2.9M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus 3.91x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M ACADACADIA Pharmaceuticals, Inc.3.91x 15.65x $278.6M $71.8M
-
Which has Higher Returns PALI or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Palisade Bio, Inc.'s net margin of 16.99%. Palisade Bio, Inc.'s return on equity of -222.18% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About PALI or ALNY?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 692.9%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 34.66%. Given that Palisade Bio, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Palisade Bio, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is PALI or ALNY More Risky?
Palisade Bio, Inc. has a beta of 1.583, which suggesting that the stock is 58.275% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock PALI or ALNY?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or ALNY?
Palisade Bio, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Palisade Bio, Inc.'s net income of -$2.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 150.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus 12.20x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M ALNYAlnylam Pharmaceuticals, Inc.12.20x 150.36x $1.1B $186.4M
-
Which has Higher Returns PALI or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Palisade Bio, Inc.'s net margin of -3.91%. Palisade Bio, Inc.'s return on equity of -222.18% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About PALI or BMRN?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 692.9%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 40.13%. Given that Palisade Bio, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Palisade Bio, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is PALI or BMRN More Risky?
Palisade Bio, Inc. has a beta of 1.583, which suggesting that the stock is 58.275% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock PALI or BMRN?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or BMRN?
Palisade Bio, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Palisade Bio, Inc.'s net income of -$2.9M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus 4.02x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M BMRNBioMarin Pharmaceutical, Inc.4.02x 23.76x $786.8M -$30.7M
-
Which has Higher Returns PALI or FOLD?
Amicus Therapeutics, Inc. has a net margin of -- compared to Palisade Bio, Inc.'s net margin of 10.24%. Palisade Bio, Inc.'s return on equity of -222.18% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About PALI or FOLD?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 692.9%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.05%. Given that Palisade Bio, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Palisade Bio, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is PALI or FOLD More Risky?
Palisade Bio, Inc. has a beta of 1.583, which suggesting that the stock is 58.275% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock PALI or FOLD?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or FOLD?
Palisade Bio, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Palisade Bio, Inc.'s net income of -$2.9M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus 7.34x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M FOLDAmicus Therapeutics, Inc.7.34x -- $169.1M $17.3M
-
Which has Higher Returns PALI or SVRA?
Savara, Inc. has a net margin of -- compared to Palisade Bio, Inc.'s net margin of --. Palisade Bio, Inc.'s return on equity of -222.18% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital PALIPalisade Bio, Inc.-- -$0.38 $3.4M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About PALI or SVRA?
Palisade Bio, Inc. has a consensus price target of $13.40, signalling upside risk potential of 692.9%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 93.43%. Given that Palisade Bio, Inc. has higher upside potential than Savara, Inc., analysts believe Palisade Bio, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PALIPalisade Bio, Inc.3 0 0 SVRASavara, Inc.6 0 0 -
Is PALI or SVRA More Risky?
Palisade Bio, Inc. has a beta of 1.583, which suggesting that the stock is 58.275% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock PALI or SVRA?
Palisade Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PALI or SVRA?
Palisade Bio, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Palisade Bio, Inc.'s net income of -$2.9M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Palisade Bio, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PALIPalisade Bio, Inc.-- -- -- -$2.9M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
46
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 21.87% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 16.79% over the past day.
